PictureDesignSwiss / Shutterstock.com
Biogen and Alkermes sued the US-Israeli generic drug maker company after it filed an Abbreviated New Drug Application, number 214206, at the US Food and Drug Administration (FDA) seeking approval to manufacture and sell a generic version of Vumerity.
According to Biogen and Alkermes, Teva’s generic infringes three patents that protect Vumerity, which Alkermes licenses exclusively to Biogen.
The patents, US numbers 8,669,281; 9,090,558; and 10,080,733 are set to expire in September 2033, according to the FDA's Orange book.
Biogen launched Vumerity in November 2019, as a successor to its blockbuster MS treatment, Tecfidera (dimethyl fumarate).
According to a report in science journal FiercePharma, the drug generated $11 million in the first half of 2020, a disappointing performance for Biogen as it faces competitive threats to its multiple sclerosis business.
In July 2020, Biogen CEO Michel Vounatsos told the journal that the next five months would be "critical" for the medicine, and that the company’s sole focus would shift from Tecfidera to Vumerity.
The decision came as a major blow to Biogen, which relied on Tecfidera for almost a third ($4.4 billion) of its 2019 sales.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox
Biogen, Teva, Alkerme, generic, MS, patent infringement, big pharma